The Food and Drug Administration granted accelerated approval to iberdomide, sold as Zenbexus, for adults with multiple myeloma who have received at least one prior line of treatment. The decision, announced on August 13, introduces the first drug in the class of cereblon E3 ligase modulators (CELMoDs) into myeloma care.
For patients weighing what comes after a first relapse, the practical significance is placement. This is not a last-resort option reserved for those who have exhausted all other options. It is approved for use as early as the second line of therapy, in a three-drug combination built around treatments myeloma patients and their oncologists already know.
The approval is accelerated, which carries specific conditions worth understanding before a treatment conversation.
Where the Drug Sits in the Treatment Sequence
Multiple myeloma is a cancer of plasma cells in the bone marrow. Most patients respond to initial treatment, and most eventually relapse. Each relapse narrows the options, which is why the point at which a new drug enters the sequence matters as much as how well it works.
Iberdomide is approved in combination with daratumumab and hyaluronidase, sold as Darzalex Faspro, and dexamethasone. Eligible patients are those who have already received at least one prior line of therapy that included a proteasome inhibitor and an immunomodulatory agent, two drug classes standard in first-line myeloma treatment.
Relapsed or refractory means the cancer either came back after responding or never responded adequately in the first place. The sequence of what comes next is one of the most consequential decisions in the course of the disease.
Iberdomide is taken by mouth at 1 milligram once daily on days one through 21 of each 28-day cycle, alongside the injected daratumumab component. It is designed as a more potent successor to older immunomodulatory drugs such as lenalidomide and pomalidomide, working by helping the body destroy proteins that myeloma cells rely on for survival.
The Trial Evidence and What It Measured
Approval rests on the phase 3 EXCALIBER-RRMM trial, which randomized 939 patients across two stages. The primary efficacy population comprised the first 420 patients assigned to the iberdomide combination, 207 patients, or to daratumumab, bortezomib, and dexamethasone, 213 patients.
At a median follow-up of 16 months, 41 percent of patients on the iberdomide regimen achieved minimal residual disease-negative complete response, compared with 21 percent on the comparator. Minimal residual disease negativity means no myeloma cells were detectable using highly sensitive testing.
That endpoint is why this approval is notable and why it comes with a caveat. This is the first FDA approval in relapsed or refractory myeloma based on minimal residual disease-negative complete response. The measure is considered predictive of longer progression-free survival, but it is a surrogate. It is not the same as demonstrating that patients live longer or go longer without their cancer returning.
The trial is ongoing, and progression-free survival is the second of its dual primary endpoints. Under accelerated approval, the FDA requires confirmatory evidence, and an indication can be withdrawn if that evidence does not materialize.
Patients whose disease was refractory to prior anti-CD38 antibody therapy or to prior bortezomib were excluded from the trial. That exclusion is important. It means the results do not tell clinicians how the combination performs in patients who have already failed those specific drugs, a group that includes many people further along in their treatment course.
Sagar Lonial, chief medical officer of the Winship Cancer Institute of Emory University and the trial's lead investigator, said in a statement from Bristol Myers Squibb that the approval "marks the anticipated arrival of a new therapeutic class." He led the company-sponsored trial, which readers should weigh alongside the data itself.
The Safety Requirements Attached to the Label
The prescribing information carries a boxed warning for embryo-fetal toxicity and for serious venous and arterial blood clots, plus warnings for low white blood cell counts, infections, and second cancers. Because of the risk to a developing fetus, the drug is available only through a restricted distribution program, a Risk Evaluation and Mitigation Strategy.
In the trial, 7.8 percent of patients discontinued the iberdomide regimen because of adverse reactions. Anyone starting therapy should discuss blood count monitoring, infection precautions, clot risk and pregnancy prevention requirements with their oncology team, and should not stop or adjust any myeloma medication without that conversation. Full prescribing information is posted on the agency's drug approval database.
Cost, Coverage and Access Questions Patients Should Raise
Newly approved oncology drugs in this category typically carry substantial list prices, and Bristol Myers Squibb has not publicly detailed pricing at launch. Patients should not assume coverage is automatic.
Practical steps matter here. Ask the oncology practice's financial navigator to verify coverage before the first cycle, not after. Medicare patients should understand whether the oral component falls under Part D and what the out-of-pocket structure looks like across the year, since the Part D out-of-pocket cap changes the math considerably compared with prior years. Commercially insured patients should ask about prior authorization requirements and whether step therapy applies.
Manufacturer patient assistance programs, independent copay foundations, and hospital charity care exist for exactly this situation. The Leukemia & Lymphoma Society and the HealthTree Foundation both maintain myeloma-specific financial navigation resources.
Access is also geographic. Combination regimens requiring infusion plus oral therapy are administered more easily at centers with established myeloma programs. Patients in rural areas may need to weigh travel against local availability, and asking whether a community oncology practice can administer the regimen is a reasonable first question.
Who This Approval Reaches and Who It Does Not
The patients most likely to benefit are those at first- or second-relapse who have received a proteasome inhibitor and an immunomodulatory agent, and whose disease is not refractory to daratumumab or bortezomib. That is a meaningful population, because it captures people relatively early in the relapse sequence when more options remain open.
Patients who have already failed anti-CD38 therapy fall outside the trial population. So do patients whose myeloma has progressed through multiple lines and who may be candidates for BCMA-directed bispecific antibodies or CAR T-cell therapy instead.
Progression-free survival data from the trial will determine whether the accelerated approval converts to full approval. The review was conducted under the FDA's Project Orbis program, which allows concurrent review with international partners, and the agency collaborated with Switzerland's Swissmedic, so a decision there may follow. Treatment guidelines from the National Comprehensive Cancer Network are typically updated after approvals of this kind, and that update will shape which patients insurers agree to cover.
Key Questions Answered
What does relapsed or refractory multiple myeloma mean?
Relapse means the cancer returned after responding to treatment. Refractory means it stopped responding or never responded adequately. Both describe a disease that requires a change in therapy.
Who is eligible for this combination?
Adults who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. It can be used as early as the first relapse.
What is accelerated approval?
A pathway allowing FDA clearance based on a measure likely to predict clinical benefit. Confirmatory evidence is required, and the approval can be withdrawn if it is not provided.
What does minimal residual disease negativity mean?
No myeloma cells were detectable using highly sensitive testing. It is among the deepest responses measurable and is considered predictive of longer progression-free survival.
Does this prove patients live longer?
Not yet. The trial's progression-free survival data are still being collected. The approval was based on response depth, not survival.
What safety warnings does the label carry?
A boxed warning for embryo-fetal toxicity and serious venous and arterial blood clots, plus warnings for neutropenia, infections, and second cancers. The drug is dispensed through a restricted program.
How should patients handle cost?
Ask the oncology practice's financial navigator to verify coverage before the first cycle, and ask about prior authorization, manufacturer assistance, and independent copay foundations.
